Skip to main content

Table 9 Duration of antibiotic use in the IFNα1b group and the control group

From: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

 

FAS

PPS

Item

IFNα1b Group

Control Group

IFNα1b Group

Control Group

n (Missing)

140 (24)

138 (22)

122 (21)

131 (20)

Mean (SD)

7.84 (3.50)

7.99 (3.78)

7.83 (3.25)

7.95 (3.83)

Median

8

8

8

8

Q1, Q3

5.0, 9.3

5.8, 10.3

6.0, 9.0

5.0, 10.5

Min, Max

1,16

1,16

1,16

1,16

95% CI

7.20, 8.49

7.30, 8.69

7.19, 8.47

7.24,8.67

Statistics

Wilcoxon rank sum test

6523

Wilcoxon rank sum test

5416

P

0.688

 

0.670